Trillium Asset Management LLC Reduces Stake in Encompass Health Co. (NYSE:EHC)

Trillium Asset Management LLC reduced its stake in Encompass Health Co. (NYSE:EHC) by 1.4% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 160,490 shares of the company’s stock after selling 2,302 shares during the quarter. Trillium Asset Management LLC owned approximately 0.16% of Encompass Health worth $14,821,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. MassMutual Private Wealth & Trust FSB grew its holdings in Encompass Health by 87.8% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 293 shares of the company’s stock valued at $27,000 after buying an additional 137 shares in the last quarter. Avior Wealth Management LLC purchased a new stake in Encompass Health in the 3rd quarter valued at $40,000. CBIZ Investment Advisory Services LLC grew its holdings in shares of Encompass Health by 38.7% during the 4th quarter. CBIZ Investment Advisory Services LLC now owns 455 shares of the company’s stock worth $42,000 after purchasing an additional 127 shares during the period. Tompkins Financial Corp purchased a new position in shares of Encompass Health during the 4th quarter worth $46,000. Finally, V Square Quantitative Management LLC grew its holdings in shares of Encompass Health by 43.8% during the 4th quarter. V Square Quantitative Management LLC now owns 581 shares of the company’s stock worth $54,000 after purchasing an additional 177 shares during the period. 97.25% of the stock is currently owned by hedge funds and other institutional investors.

Encompass Health Price Performance

EHC stock opened at $97.53 on Wednesday. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.05 and a quick ratio of 1.04. The firm has a market capitalization of $9.82 billion, a P/E ratio of 21.87, a P/E/G ratio of 2.31 and a beta of 0.92. The business’s 50-day moving average is $97.60 and its two-hundred day moving average is $97.05. Encompass Health Co. has a 1 year low of $76.11 and a 1 year high of $104.55.

Encompass Health (NYSE:EHC) last posted its quarterly earnings results on Thursday, February 6th. The company reported $1.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.05 by $0.12. Encompass Health had a return on equity of 17.56% and a net margin of 8.48%. Analysts anticipate that Encompass Health Co. will post 4.8 earnings per share for the current fiscal year.

Encompass Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Stockholders of record on Tuesday, April 1st will be given a dividend of $0.17 per share. This represents a $0.68 annualized dividend and a dividend yield of 0.70%. The ex-dividend date of this dividend is Tuesday, April 1st. Encompass Health’s dividend payout ratio (DPR) is presently 15.25%.

Insider Transactions at Encompass Health

In other news, CAO Andrew L. Price sold 5,042 shares of the firm’s stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $98.29, for a total transaction of $495,578.18. Following the sale, the chief accounting officer now owns 69,164 shares of the company’s stock, valued at approximately $6,798,129.56. This trade represents a 6.79 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 2.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on EHC. KeyCorp increased their price target on Encompass Health from $117.00 to $120.00 and gave the stock an “overweight” rating in a report on Monday, February 10th. StockNews.com upgraded Encompass Health from a “hold” rating to a “buy” rating in a report on Saturday, February 15th. Royal Bank of Canada restated an “outperform” rating and set a $110.00 target price on shares of Encompass Health in a report on Tuesday, February 11th. Barclays raised their target price on Encompass Health from $116.00 to $118.00 and gave the company an “overweight” rating in a report on Friday, February 7th. Finally, William Blair restated an “outperform” rating on shares of Encompass Health in a report on Friday, February 7th. Ten research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $107.67.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.